Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Gujarat Themis Biosyn

GUJTHEM
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Gujarat Themis Biosyn Share price and Fundamental Analysis

View All Details
View All Details
Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.
Company Incorporation1981
ChairmanDinesh S Patel
Head QuartersMumbai
Previous NameNA

Key Metrics

Market Cap (Cr)
4,044.25
PE Ratio
82.85
Industry P/E
30.53
PEG Ratio
-4.72
ROE
19.64%
ROCE
23.63%
ROA
16.19%
Total Debt (Cr)
30.47
Debt to Equity
0.12
Dividend Yield
0.18%
EPS
4.48
Book Value & P/B
22.8 x 16.28
Face Value
1
Outstanding Shares(Cr)
10.9
Current Ratio
2.63
EV to Sales
26.94

Included In

+More

Stock Returns

1 Week+6.62%
1 Month+10.17%
6 Months+52.59%
1 Year+52.59%
3 Years+52.59%
5 Years+52.59%
no_data

No Stocks

Smart Score

2.8
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Feb 25

Promoters : 70.86%

FIIs : 1.48%

DIIs : 1.16%

Public : 26.50%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 3.3% of holding in February 2025 Qtr
FII Shareholding Increased by 0.06% to 1.48% in February 2025 Qtr
DII Shareholding Decreased by 0.01% to 1.16% in February 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Gujarat Themis Biosyn Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Gujarat Themis Biosyn Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.

Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL.

During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of anti-tuberculosis products and other antibiotics.

The company is constantly identifying new areas for diversification and also capacity expansion of exisiting product in order to further reduction in cost of production and increase in turnover.

Gujarat Themis Biosyn Share Price

Gujarat Themis Biosyn share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Gujarat Themis Biosyn Market Cap

Market capitalization of Gujarat Themis Biosyn indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Gujarat Themis Biosyn is valued compared to its competitors.

Gujarat Themis Biosyn PE Ratio

Gujarat Themis Biosyn PE ratio helps investors understand what is the market value of each stock compared to Gujarat Themis Biosyn 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Gujarat Themis Biosyn PEG Ratio

The PEG ratio of Gujarat Themis Biosyn evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Gujarat Themis Biosyn ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Gujarat Themis Biosyn generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Gujarat Themis Biosyn ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Gujarat Themis Biosyn in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Gujarat Themis Biosyn Total Debt

Total debt of Gujarat Themis Biosyn shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Gujarat Themis Biosyn Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Gujarat Themis Biosyn compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Gujarat Themis Biosyn CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Gujarat Themis Biosyn over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Gujarat Themis Biosyn Technical Analysis

Technical analysis of Gujarat Themis Biosyn helps investors get an insight into when they can enter or exit the stock. Key components of Gujarat Themis Biosyn Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Gujarat Themis Biosyn shares often struggle to rise above due to selling pressure.

Gujarat Themis Biosyn Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Gujarat Themis Biosyn ’s financial health and profitability.

Gujarat Themis Biosyn Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Gujarat Themis Biosyn Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Gujarat Themis Biosyn Financials

The financials of Gujarat Themis Biosyn provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Gujarat Themis Biosyn Profit and Loss Statements

The profit and loss statement of Gujarat Themis Biosyn highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Gujarat Themis Biosyn .

Gujarat Themis Biosyn Balance Sheet

The balance sheet presents a snapshot of Gujarat Themis Biosyn ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Gujarat Themis Biosyn Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.